Remix Therapeutics to Go Public via Reverse Merger with Passage Bio
Remix Therapeutics is set to go public through a reverse merger with Passage Bio. The deal, expected to close in Q4 2026, will result in the new entity trading under the ticker RMTX. Remix investors are projected to own about 93% of the combined company.
Tickers: $PASG
Topics: biotech gene therapy IPO public offering